Sebastiano Buti
Sebastiano Buti
Department of Medicine and Surgery, University of Parma, Parma, Italy.
Email verificata su - Home page
Citata da
Citata da
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ...
Journal for ImmunoTherapy of Cancer 7 (1), 57, 2019
Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab
U De Giorgi, G Procopio, D Giannarelli, R Sabbatini, A Bearz, S Buti, ...
Clinical Cancer Research 25 (13), 3839-3846, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ...
The oncologist, 10.1634/theoncologist.2018-0618, 2019
Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients
A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ...
Clinical lung cancer 20 (4), 237-247. e1, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the …
E Verzoni, G Cartenì, E Cortesi, D Giannarelli, A De Giglio, R Sabbatini, ...
Journal for ImmunoTherapy of Cancer 7 (1), 99, 2019
Chemotherapy in metastatic renal cell carcinoma today? A systematic review
S Buti, M Bersanelli, A Sikokis, F Maines, F Facchinetti, E Bria, A Ardizzoni, ...
Anti-Cancer Drugs, 2013
The Circulating Pool of Functionally Competent NK and CD8+ Cells Predicts the Outcome of anti-PD1 Treatment in Advanced NSCLC
G Mazzaschi, F Facchinetti, G Missale, D Canetti, D Madeddu, A Zecca, ...
Lung Cancer 127, 153-163, 2019
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
C Masini, C Iotti, U De Giorgi, RS Bellia, S Buti, F Salaroli, I Zampiva, ...
European Urology, 2021
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death …
A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ...
European Journal of Cancer 128, 17-26, 2020
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study
CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ...
JAMA oncology 7 (12), 1856-1861, 2021
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and …
S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ...
European Journal of Cancer 142, 18-28, 2021
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors
M Santoni, A Conti, S Partelli, C Porta, CN Sternberg, G Procopio, ...
Annals of surgical oncology 22 (6), 2094-2100, 2015
Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology …
R Passalacqua, C Caminiti, S Buti, C Porta, R Camisa, L Braglia, ...
Journal of Immunotherapy 37 (9), 440-447, 2014
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): A double-blind, randomised, phase 3 trial
RJ Motzer, P Russo, V Grünwald, Y Tomita, B Zurawski, O Parikh, S Buti, ...
The Lancet 401 (10379), 821-832, 2023
Soluble PD-L1 and Circulating CD8+ PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients
G Mazzaschi, R Minari, A Zecca, A Cavazzoni, V Ferri, C Mori, A Squadrilli, ...
Lung Cancer 148, 1-11, 2020
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme
U De Giorgi, G Cartenì, D Giannarelli, U Basso, L Galli, E Cortesi, ...
BJU international, doi: 10.1111/bju.14461, 2018
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis
M Bersanelli, S Buti
World Journal of Clinical Oncology 8 (1), 37-53, 2017
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors
L Schirosi, N Nannini, D Nicoli, A Cavazza, R Valli, S Buti, L Garagnani, ...
Annals of oncology 23 (9), 2409-2414, 2012
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation
A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ...
Journal for ImmunoTherapy of Cancer 8 (2), e001403, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50%
A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ...
Cancer Immunology, Immunotherapy 69 (11), 2209-2221, 2020
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20